Retinal Disease Research & Development

Developing Sustained-Release Drug Delivery Platforms for Retinal Diseases

Glaukos is developing multiple micro-invasive, bioerodible, sustained-release drug delivery platforms designed to be used in the treatment of various retinal disease, including age-related macular degeneration (AMD) and diabetic macular edema.

Sign Up For Updates

Retinal Diseases Vary Widely, Can Affect Any Part of the Retina, and Are Leading Causes of Blindness Worldwide

The thin layer of tissue on the inside back wall of the eye, the retina, contains millions of cells that receive, organize and send visual information through the optic nerve to the brain, enabling vision. AMD and diabetic retinopathies are the most common degenerative retinal diseases. Market Scope estimates that approximately 28 million people in the United States suffer from some type of retinal disease or condition, including approximately 17 million people with AMD.

Retinal Disease Programs Currently in Development

Retinal Disease Research Area

Triamcinolone Acetonide SR (RVO & DME)

Developing formulations to release triamcinolone acetonide for up to 6 months.

Retinal Disease Research Area

Multi-Kinase Inhibitor SR (Wet AMD, RVO & DME)

Developing a multi-kinase inhibitor small molecule sustained-release delivery system.

Retinal Disease Research Area

Anti-VEGF SR (Wet, RVO & DME)

Developing sustained release, hydrogelbased, erodible implant with protein stabilization technology.

Sign up to receive the latest information on our retinal disease programs, including research findings and more

Stay Connected

Glaukos will use the information you provide on this form to be in touch with you.*
This field is for validation purposes and should be left unchanged.